Loading clinical trials...
Loading clinical trials...
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of Transcatheter Arterial Infusion of Paclitaxel Cationic Liposome Combined With Systemic Therapy in Participants With Advanced Hepatocellular Carcinoma for Second-line Treatment
Conditions
Interventions
HA131
Enlonstobart Injection
+2 more
Start Date
December 23, 2025
Primary Completion Date
June 26, 2028
Completion Date
February 3, 2029
Last Updated
December 15, 2025
NCT07493044
NCT07039201
NCT06737913
NCT04523493
NCT01101906
NCT04212221
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions